Predictors of suboptimal virologic response to highly active antiretroviral therapy among human immunodeficiency virus-infected adolescents: Analyses of the Reaching for Excellence in Adolescent Care and Health (REACH) Project

Archives of Pediatrics and Adolescent Medicine

Volumn 163, Issue 12, 2009, Pages 1100-1105

  Ding, Helen ^a,b,c   Wilson, Craig M ^c   Modjarrad, Kayvon ^d   McGwin Jr , Gerald ^c   Tang, Jianming ^c   Vermund, Sten H ^d  

^a Ginn Group Inc   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD; CONTROLLED STUDY; DEPRESSION; DRUG ABUSE; DRUG EXPOSURE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENETICS; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RNA ANALYSIS; SCHOOL CHILD; SEX DIFFERENCE; TREATMENT RESPONSE; VIRUS LOAD;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; FEMALE; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MALE; PATIENT COMPLIANCE; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 71549158199     PISSN: 10724710     EISSN: 15383628     Source Type: Journal    
DOI: 10.1001/archpediatrics.2009.204     Document Type: Article

References (46)

1. Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2006. Atlanta, GA: Centers for Disease Control and Prevention; 2008.
2. Rosenberg PS, Biggar RJ. Trends in HIV incidence among young adults in the United States. JAMA. 1998;279(23):1894-1899. (Pubitemid 28299286)
3. Hall HI, Song R, Rhodes P, et al; HIV Incidence Surveillance Group. Estimation of HIV incidence in the United States. JAMA. 2008;300(5):520-529.
4. Rangel MC, Gavin L, Reed C, Fowler MG, Lee LM. Epidemiology of HIV and AIDS among adolescents and young adults in the United States. J Adolesc Health. 2006;39(2):156-163. (Pubitemid 44081873)
5. Murphy DA, Mitchell R, Vermund SH, Futterman D; Adolescent Medicine HIV/AIDS Research Network. Factors associated with HIV testing among HIV-positive and HIV-negative high-risk adolescents: the REACH Study. Reaching for Excellence in Adolescent Care and Health. Pediatrics. 2002;110(3):e36. http://pediatrics.aappublications.org/cgi/content/full/110/3/e36. Accessed December 15, 2008.
6. Obermeyer CM, Osborn M. The utilization of testing and counseling for HIV: a review of the social and behavioral evidence. Am J Public Health. 2007;97(10):1762-1774. (Pubitemid 351182283)
7. Vermund SH, Wilson CM. Barriers to HIV testing: where next? Lancet. 2002;360(9341):1186-1187. (Pubitemid 35232714)
8. Johnson RL, Martinez J, Botwinick G, et al. Introduction: what youth need: adapting HIV care models to meet the lifestyles and special needs of adolescents and young adults. J Adolesc Health. 2003;33(2)(suppl):4-9. (Pubitemid 36918439)
9. Tylee A, Haller DM, Graham T, Churchill R, Sanci LA. Youth-friendly primary-care services: how are we doing and what more needs to be done? Lancet. 2007;369(9572):1565-1573. (Pubitemid 46670279)
10. Johnson RL, Botwinick G, Sell RL, et al. The utilization of treatment and case management services by HIV-infected youth. J Adolesc Health. 2003;33(2)(suppl):31-38. (Pubitemid 36918442)
11. Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network. Barriers to HAART adherence among human immunodeficiency virus-infected adolescents. Arch Pediatr Adolesc Med. 2003;157(3):249-255.
12. DeRossi A. Primary HIV infection in infants: impact of highly active antiretroviral therapy on the natural course. J Biol Regul Homeost Agents. 2002;16(1):53-57. (Pubitemid 34495590)
13. Detels R, Muñoz A, McFarlane G, et al; Multicenter AIDS Cohort Study Investigators. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280(17):1497-1503.
14. Erb P, Battegay M, Zimmerli W, Rickenbach M, Egger M. Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort: Swiss HIV Cohort Study. Arch Intern Med. 2000;160(8):1134-1140. (Pubitemid 30227023)
15. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17(13):1907-1915. (Pubitemid 37070276)
16. Press N, Tyndall MW, Wood E, Hogg RS, Montaner JS. Virologic and immunologic response, clinical progression, and highly active antiretroviral therapy adherence. J Acquir Immune Defic Syndr. 2002;31(suppl 3):S112-S117. (Pubitemid 35453569)
17. Barreiro PM, Dona MC, Castilla J, Soriano V. Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. AIDS. 1999;13(4):525-526.
18. Florence E, Lundgren J, Dreezen C, et al; EuroSIDA Study Group. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4(3):255-262. (Pubitemid 36949882)
19. Jevtović D, Salemović D, Ranin J, Pesić I, Zerjav S, Djurković-Djaković O. The dissociation between virological and immunological responses to HAART. Biomed Pharmacother. 2005;59(8):446-451. (Pubitemid 41383838)
20. Le Moing V, Thiebaut R, Chene G, et al; ANRS CO8 (APROCO/COPILOTE) Study Group. Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med. 2007;8(3):156-163.
21. Rogers AS, Futterman DK, Moscicki AB, Wilson CM, Ellenberg J, Vermund SH. The REACH Project of the Adolescent Medicine HIV/AIDS Research Network: design, methods, and selected characteristics of participants. J Adolesc Health. 1998;22(4):300-311. (Pubitemid 28163251)
22. Wilson CM, Houser J, Partlow C, Rudy BJ, Futterman DC, Friedman LB; Adolescent Medicine HIV/AIDS Research Network. The REACH (Reaching for Excellence in Adolescent Care and Health) project: study design, methods, and population profile. J Adolesc Health. 2001;29(3)(suppl):8-18.
23. Radloff LS. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385-401. doi:10.1177/014662167700100306.
24. Murphy DA, Wilson CM, Durako SJ, Muenz LR, Belzer M; Adolescent Medicine HIV/AIDS Research Network. Antiretroviral medication adherence among the REACH HIV-infected adolescent cohort in the USA. AIDS Care. 2001;13(1):27-40.
25. Reisner SL, Mimiaga MJ, Skeer M, Perkovich B, Johnson CV, Safren SA. A review of HIV antiretroviral adherence and intervention studies among HIV-infected youth. Top HIV Med. 2009;17(1):14-25.
26. Tang J, Wilson CM, Meleth S, et al; REACH Study Group. Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS. 2002;16(17):2275-2284. (Pubitemid 35449013)
27. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41(RR-17):1-19.
28. Flynn PM, Rudy BJ, Lindsey JC, et al; PACTG 381 Study Team. Long-term observation of adolescents initiating HAART therapy: three-year follow-up. AIDS Res Hum Retroviruses. 2007;23(10):1208-1214.
29. Rudy BJ, Lindsey JC, Flynn PM, et al; Pediatric Aids Clinical Trials Group 381 Study Team. Immune reconstitution and predictors of virologic failure in adolescents infected through risk behaviors and initiating HAART: week 60 results from the PACTG 381 cohort. AIDS Res Hum Retroviruses. 2006;22(3):213-221.
30. Ferris M, Burau K, Constantin AM, et al. Influence of institutionalization on time to HIV disease progression in a cohort of Romanian children and teens. Pediatrics. 2007;120(6):e1476-e1480. (Pubitemid 350223667)
31. Gouws E, Stanecki KA, Lyerla R, Ghys PD. The epidemiology of HIV infection among young people aged 15-24 years in southern Africa. AIDS. 2008;22(suppl 4):S5-S16.
32. Kabue MM, Kekitiinwa A, Maganda A, Risser JM, Chan W, Kline MW. Growth in HIV-infected children receiving antiretroviral therapy at a pediatric infectious diseases clinic in Uganda. AIDS Patient Care STDS. 2008;22(3):245-251.
33. Braithwaite RS, Kozal MJ, Chang CC, et al. Adherence, virological and immunological outcomes for HIV-infected veterans starting combination antiretroviral therapies. AIDS. 2007;21(12):1579-1589.
34. Gandhi M, Ameli N, Bacchetti P, et al; Women's Interagency HIV Study (WIHS). Protease inhibitor levels in hair strongly predict virologic response to treatment. AIDS. 2009;23(4):471-478.
35. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282(12):1135-1141. (Pubitemid 29441957)
36. Chesney M. Adherence to HAART regimens. AIDS Patient Care STDS. 2003;17(4):169-177.
37. García de Olalla P, Knobel H, Carmona A, Guelar A, López-Colomés JL, Caylà JA. Impact of adherence and highly active antiretroviral therapy on survival in HIV-infected patients. J Acquir Immune Defic Syndr. 2002;30(1):105-110. (Pubitemid 34506694)
38. Gifford AL, Bormann JE, Shively MJ, Wright BC, Richman DD, Bozzette SA. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23(5):386-395.
39. Gross R, Bilker WB, Friedman HM, Strom BL. Effect of adherence to newly initiated antiretroviral therapy on plasma viral load. AIDS. 2001;15(16):2109-2117. (Pubitemid 33101818)
40. Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med. 2007;146(8):564-573. (Pubitemid 351650537)
41. Hein K, Futterman D. Guidelines for the care of children and adolescents with HIV infection: medical management in HIV-infected adolescents. J Pediatr. 1991;119(1, pt 2):S18-S20.
42. D'Angelo LJ, Abdalian SE, Sarr M, Hoffman N, Belzer M; Adolescent Medicine HIV/AIDS Research Network. Disclosure of serostatus by HIV infected youth: the experience of the REACH study: Reaching for Excellence in Adolescent Care and Health. J Adolesc Health. 2001;29(3)(suppl):72-79.
43. Tornero C, Santamaria A, Gil E. The presence of a caregiving relative implicated in the administration of antiretroviral drug administration improves virologic response. J Acquir Immune Defic Syndr. 2007;46(5):658. (Pubitemid 350191064)
44. Aidala AA, Lee G, Abramson DM, Messeri P, Siegler A. Housing need, housing assistance, and connection to HIV medical care. AIDS Behav. 2007;11(6)(suppl):101-115. (Pubitemid 47620333)
45. Martinez J, Bell D, Dodds S, et al. Transitioning youths into care: linking identified HIV-infected youth at outreach sites in the community to hospital-based clinics and or community-based health centers. J Adolesc Health. 2003;33(2)(suppl):23-30. (Pubitemid 36918441)
46. Futterman DC. HIV and AIDS in adolescents. Adolesc Med Clin. 2004;15(2):369-391.